Prevention of human rabies: a challenge for the European Union and the European Economic Area.
bats
dog
lyssaviruses
rabies
travel
vaccination
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
6
1
2021
Statut:
ppublish
Résumé
Rabies is enzootic in over one hundred countries worldwide. In the European Union/European Economic Area (EU/EEA), the vast majority of human rabies cases are travellers bitten by dogs in rabies-enzootic countries, mostly in Asia and Africa. Thus, EU/EEA travellers visiting rabies enzootic countries should be aware of the risk of being infected with the rabies virus when having physical contact with mammals. They should consider pre-exposure vaccination following criteria recommended by the World Health Organization and if unvaccinated, immediately seek medical attention in case of bites or scratches from mammals. As the majority of the EU/EEA countries are free from rabies in mammals, elimination of the disease (no enzootic circulation of the virus and low number of imported cases) has been achieved by 2020. However, illegal import of potentially infected animals, mainly dogs, poses a risk to public health and might threaten the elimination goal. Additionally, newly recognised bat lyssaviruses represent a potential emerging threat as the rabies vaccine may not confer protective immunity. To support preparedness activities in EU/EEA countries, guidance for the assessment and the management of the public health risk related to rabies but also other lyssaviruses, should be developed.
Identifiants
pubmed: 32975184
doi: 10.2807/1560-7917.ES.2020.25.38.2000158
pmc: PMC7533618
doi:
Substances chimiques
Rabies Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Travel Med. 2019 Feb 1;26(Suppl 1):S3-S9
pubmed: 30476212
J Comp Pathol. 2006 Feb-Apr;134(2-3):190-201
pubmed: 16545840
Emerg Infect Dis. 2011 Apr;17(4):753-4
pubmed: 21470483
Vaccine. 2019 Apr 17;37(17):2285-2287
pubmed: 30922698
J Med Virol. 2010 Jul;82(7):1255-65
pubmed: 20513093
J Clin Microbiol. 2015 Jun;53(6):1979-82
pubmed: 25854482
Emerg Infect Dis. 2010 Aug;16(8):1318-9
pubmed: 20678336
PLoS Negl Trop Dis. 2009 Jul 28;3(7):e428
pubmed: 19636367
Euro Surveill. 2007 May 31;12(5):E070531.5
pubmed: 17868587
Emerg Infect Dis. 2009 Feb;15(2):280-4
pubmed: 19193273
Euro Surveill. 2015 Feb 12;20(6):
pubmed: 25695478
Epidemiol Infect. 2003 Dec;131(3):1029-39
pubmed: 14959767
Rev Inst Med Trop Sao Paulo. 2015 Jan-Feb;57(1):63-72
pubmed: 25651328
Vet Rec. 2015 May 30;176(22):558
pubmed: 26025705
Dev Biol (Basel). 2004;119:185-204
pubmed: 15747421
Viruses. 2019 Sep 24;11(10):
pubmed: 31554170
Virol J. 2014 Apr 07;11:63
pubmed: 24708671
Vaccine. 2012 Jan 5;30(2):126-33
pubmed: 22085557
Trop Med Infect Dis. 2019 Sep 30;4(4):
pubmed: 31575054
J R Soc Med. 2002 Jan;95(1):9-13
pubmed: 11773344
J Vet Med B Infect Dis Vet Public Health. 2004 Mar;51(2):49-54
pubmed: 15030600
EFSA J. 2019 Dec 11;17(12):e05926
pubmed: 32626211
PLoS Negl Trop Dis. 2018 Nov 13;12(11):e0006951
pubmed: 30422981
Transpl Infect Dis. 2015 Jun;17(3):389-95
pubmed: 25851103
Euro Surveill. 2012 May 10;17(19):
pubmed: 22607965
Euro Surveill. 2012 Mar 22;17(12):
pubmed: 22490309
J Infect Dis. 1982 May;145(5):715-9
pubmed: 7077094